`Application No:
`1 8/250,92 1
`Foreign Priority claimed:
`35 USC 119 (a-d) conditions met:
`
`Verified and Acknowledged:
`
`Title:
`
`©No
`OvYes
`LlyYes
`No
`L_] Met After Allowance
`
`
`
`
`/GIGI G HUANG/
`GH
`Examiner's Signature
`Initials
`
`DEGRADANT COMPOUNDIN A MEDICAMENT
`
`
`
`FILINGor 371(c) DATE
`
`CLASS
`
`GROUP ART UNIT
`
`ATTORNEY DOCKETNO.
`
`
`
`
`
`
`
`
`04/27/2023
`
`RULE
`
`514
`
`1613
`
`4902.0110003
`
`
`
`APPLICANTS
`
`VISUS THERAPEUTICS, INC., Seattle, WA, UNITED STATES
`
`INVENTORS
`
`Rhett Mead SCHIFFMAN, Laguna Beach, CA, UNITED STATES
`
`Bruce Alan FIRESTONE,Irvine, CA, UNITED STATES
`
`CONTINUING DATA
`
`This application is a 371 of PCT/US2021/057720 11/02/2021
`
`PCT/US2021/057720 has PRO of 63257024 10/18/2021
`
`PCT/US2021/057720 has PRO of 63162367 03/17/2021
`
`PCT/US2021/057720 has PRO of 63108720 11/02/2020
`
`FOREIGN APPLICATIONS
`
`IF REQUIRED, FOREIGN LICENSE GRANTED**
`
`08/24/2023
`
`** SMALL ENTITY **
`
`STATE OR COUNTRY
`
`UNITED STATES
`
`ADDRESS
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`1101 K Street, NW
`
`10th Floor
`
`WASHINGTON, DC 20005
`
`UNITED STATES
`
`FILING FEE RECEIVED
`
`$504
`
`